Nordic Capital announces closing of the €9.6bn sale of Nycomed
Nordic Capital Funds V and VI (“Nordic Capital”) today announced the completion of the sale of Nycomed A/S (“Nycomed”) to the listed Japanese company Takeda Pharmaceutical Company LimitedThe transaction, valued at €9.6bn, was agreed on 19 May 2011 and excludes the US based dermatology and topical generics unit Fougera, which is being retained by the Nordic Capital-lead owner group. Interesting aspects of the transaction include: (i) the largest private equity trade sale in Europe and the third largest ever globally; (ii) among the largest capital gains on a private equity